AVADEL PHARMACEUTICALS PLC
AVDL$1.34B
Small CapNASDAQPharmaceutical PreparationsPharmaceutical industry🇺🇸North AmericaDUBLIN 2188 employees
Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Feb 15, 2026
7dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
⭐Phase 3Next
FT218 Phase 3 Results Expected
February 2026~FT218150
Primary completion for FT218 trial (NCT06525077) in Idiopathic Hypersomnia
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
FT218 | Phase 3 | Narcolepsy | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
AVDL News